Summit therapeutics inc.SMMT.US Overview
SMMT Overall Performance
SMMT AI Analysis & Strategy
SMMT Recent Performance
1.12%
Summit therapeutics inc.
0.81%
Avg of Sector
-1.14%
S&P500
SMMT PowerScanner
SMMT Key Information
SMMT Valuation Metrics
SMMT Earnings Table
SMMT Profile
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.